FDA label
What is Brilinta used for?
Brilinta contains ticagrelor. The FDA-approved uses below are quoted from the Indications and Usage section of its DailyMed label.
Source: DailyMed SPL label file dated 2026-10-23. Publisher page
The FDA label for Brilinta lists 3 uses: Acute Coronary Syndrome or a History of Myocardial Infarction; Coronary Artery Disease but No Prior Stroke or Myocardial Infarction; Acute Ischemic Stroke or Transient Ischemic Attack (TIA).
Run it in Rivvi
Which 2027 plans near you dropped or restricted Brilinta?
Tier changes and new prior auth, step therapy or quantity limits, plan by plan.
Free to start. Opens Rivvi, the AI workspace for healthcare teams.
Brilinta, tablet
Indications and Usage, quoted from the label by AstraZeneca Pharmaceuticals LP (NDA022433). Cross-references to other label sections are left out.
Acute Coronary Syndrome or a History of Myocardial Infarction
BRILINTA is indicated to reduce the risk of cardiovascular (CV) death, myocardial infarction (MI), and stroke in patients with acute coronary syndrome (ACS) or a history of MI. For at least the first 12 months following ACS, it is superior to clopidogrel.
BRILINTA also reduces the risk of stent thrombosis in patients who have been stented for treatment of ACS.
Coronary Artery Disease but No Prior Stroke or Myocardial Infarction
BRILINTA is indicated to reduce the risk of a first MI or stroke in patients with coronary artery disease (CAD) at high risk for such events. While use is not limited to this setting, the efficacy of BRILINTA was established in a population with type 2 diabetes mellitus (T2DM).
Acute Ischemic Stroke or Transient Ischemic Attack (TIA)
BRILINTA is indicated to reduce the risk of stroke in patients with acute ischemic stroke (NIH Stroke Scale score ≤5) or high-risk transient ischemic attack (TIA).
Source: DailyMed label, set id f7b3f443-e83d-4bf2-0e96-023448fed9a8, version 56, effective May 7, 2026. NDC 0186-0776, one of 4 listings for this product.
Questions
What is Brilinta used for?
The FDA label for Brilinta lists 3 uses: Acute Coronary Syndrome or a History of Myocardial Infarction; Coronary Artery Disease but No Prior Stroke or Myocardial Infarction; Acute Ischemic Stroke or Transient Ischemic Attack (TIA).
What drug class is Brilinta?
FDA lists ticagrelor in the P2Y12 Platelet Inhibitor established pharmacologic class.
Does this page cover off-label uses or dosing?
No. This page shows only the Indications and Usage section of the FDA label. Ask a pharmacist or prescriber about dosing.